# Resource Summary Report

Generated by SPARC SAWG on Aug 9, 2026

## pCMV_BE4max

RRID:Addgene_112093
Type: Plasmid

### Proper Citation

RRID:Addgene_112093

### Plasmid Information

**URL:** http://www.addgene.org/112093

**Proper Citation:** RRID:Addgene_112093

**Insert Name:** BE4max

**Organism:** Homo sapiens

**Bacterial Resistance:** Ampicillin

**Defining Citation:** PMID:29813047

**Vector Backbone Description:** Vector Backbone:pCMV; Vector Types:Mammalian Expression, CRISPR; Bacterial Resistance:Ampicillin

**Plasmid Name:** pCMV_BE4max

**Record Creation Time:** 20220422T221546+0000

**Record Last Update:** 20260808T080445+0000

### Ratings and Alerts

No rating or validation information has been found for pCMV_BE4max.

No alerts have been found for pCMV_BE4max.

### Data and Source Information

**Source:** Addgene

### Usage and Citation Metrics

We found 35 mentions in open access literature.

**Listed below are recent publications.** The full list is available at SPARC SAWG .


Apaydin DC, et al. (2026) Lipid nanoparticle-based non-viral in situ gene editing of congenital ichthyosis-causing mutations in human skin models. Cell stem cell, 33(2), 233.

Ng BG, et al. (2026) A homozygous nonsense variant in the oligosaccharyltransferase complex gene, RPN1, causes a congenital disorder of glycosylation. HGG advances, 7(3), 100604.

Hwang HY, et al. (2025) Engineered Sdd7 cytosine base editors with enhanced specificity. Nature communications, 16(1), 5881.

Simon S, et al. (2025) Design of sensitive monospecific and bispecific synthetic chimeric T cell receptors for cancer therapy. Nature cancer, 6(4), 647.

Qian Y, et al. (2025) Double-stranded DNA deaminase DddAE1347A can increase the efficiency and targeting range of cytidine base editors. Genome biology, 26(1), 391.

Berríos KN, et al. (2024) Cooperativity between Cas9 and hyperactive AID establishes broad and diversifying mutational footprints in base editors. Nucleic acids research, 52(4), 2078.

Choi DE, et al. (2024) Base editing strategies to convert CAG to CAA diminish the disease-causing mutation in Huntington's disease. eLife, 12.

Naiisseh B, et al. (2024) Context base editing for splice correction of IVSI-110 ?-thalassemia. Molecular therapy. Nucleic acids, 35(2), 102183.

Simon S, et al. (2024) Sensitive bispecific chimeric T cell receptors for cancer therapy. Research square.

Hu Y, et al. (2024) Engineering miniature CRISPR-Cas Un1Cas12f1 for efficient base editing. Molecular therapy. Nucleic acids, 35(2), 102201.

Sifri C, et al. (2023) An AlphaFold2 map of the 53BP1 pathway identifies a direct SHLD3-RIF1 interaction critical for shieldin activity. EMBO reports, 24(8), e56834.

Papaioannou NY, et al. (2023) High-efficiency editing in hematopoietic stem cells and the HUDEP-2 cell line based on in vitro mRNA synthesis. Frontiers in genome editing, 5, 1141618.

Rieffer AE, et al. (2023) APOBEC Reporter Systems for Evaluating diNucleotide Editing Levels. The CRISPR journal, 6(5), 430.

Choi DE, et al. (2023) Base editing strategies to convert CAG to CAA diminish the disease-causing mutation in Huntington's disease. bioRxiv : the preprint server for biology.

Fiumara M, et al. (2023) Genotoxic effects of base and prime editing in human hematopoietic stem cells. Nature biotechnology.

Chen S, et al. (2022) Efficient C-to-G Base Editing with Improved Target Compatibility Using Engineered Deaminase-nCas9 Fusions. The CRISPR journal, 5(3), 389.

Xiu K, et al. (2022) Delivery of CRISPR/Cas9 Plasmid DNA by Hyperbranched Polymeric Nanoparticles Enables Efficient Gene Editing. Cells, 12(1).

Liu Z, et al. (2022) Inhibition of base editors with anti-deaminases derived from viruses. Nature communications, 13(1), 597.

Yuan Q, et al. (2022) Multiplex base- and prime-editing with drive-and-process CRISPR arrays. Nature communications, 13(1), 2771.

Zhou J, et al. (2022) Eliminating predictable DNA off-target effects of cytosine base editor by using dual guiders including sgRNA and TALE. Molecular therapy : the journal of the American Society of Gene Therapy, 30(7), 2443.